PetVivo CEO John Lai on the Long Term Investment Potential of veterinary biotech and medical devices
Summary
Chris discusses the recent developments at Pet Vivo Holdings with CEO John Lei, focusing on the strategic acquisition of PZO Bio, a spin-off from the University of Connecticut. This acquisition integrates nano fiber technology with Pet Vivo's existing 'Spring' technology, which reportedly allows for the regeneration of cartilage within 60 days. The thesis is that this technology moves beyond simply masking pain with pharmaceuticals and addresses the root cause of osteoarthritis and joint lameness.
The market outlook presented is substantial, with the U.S. animal joint treatment market estimated at $5 billion and the global human market for joint replacement and osteoarthritis exceeding $100 billion. Chris notes that the company is currently valued at a market cap of approximately $30 million, which suggests significant upside if they successfully transition into human therapeutics. The company expects to file for human clinical trials (IDE) with the FDA by late 2024 or early 2025.
Mentioned Stocks
Reasoning: Chris is 'super excited' about the company's trajectory and the technology's ability to regenerate cartilage. He points to the massive discrepancy between the company's $30 million market cap and the $100 billion human healthcare opportunity. Furthermore, he highlights the clinical success in 16,000 animals and the upcoming FDA filing for human trials as strong bullish indicators.